Impact of matrix metalloproteinase-9 overexpression on synaptic excitatory transmission and its plasticity in rat CA3-CA1 hippocampal pathway

Journal of Physiology and Pharmacology

Volumn 66, Issue 2, 2015, Pages 309-315

  Wiera, Grzegorz ^a,b   Szczot, M ^a   Wojtowicz, T ^a   Lebida, K ^a   Koza, P ^c   Mozrzymas, Jerzy W ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Field excitatory postsynaptic potentials; High frequency stimulation; Hippocampus; Long term potentiation; Metalloproteinase; Miniature excitatory postsynaptic potentials; Synapse

Indexed keywords

GELATINASE B; SYNAPSIN I;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGRADATION KINETICS; ENZYME ACTIVITY; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; INHIBITORY POSTSYNAPTIC POTENTIAL; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PATCH CLAMP TECHNIQUE; PRESYNAPTIC POTENTIAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RAT; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSGENIC ANIMAL; WISTAR RAT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; MALE; MATRIX METALLOPROTEINASE 9; NEURONAL PLASTICITY; PYRAMIDAL CELLS; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION;

EID: 84927517137     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wlodarczyk J, Mukhina I, Kaczmarek L, Dityatev A. Extracellular matrix molecules, their receptors, and secreted proteases in synaptic plasticity. Dev Neurobiol 2011; 71: 1040-1053.
2. Huntley GW. Synaptic circuit remodelling by matrix metalloproteinases in health and disease. Nat Rev Neurosci 2012; 13: 743-757.
3. Kiczak L, Tomaszek A, Bania J, et al. Matrix metalloproteinase 9/neutrophil gelatinase associated lipocalin/tissue inhibitor of metalloproteinasess type 1 complexes are localized within cardiomyocytes and serve as a reservoir of active metalloproteinase in porcine female myocardium. J Physiol Pharmacol 2014; 65: 365-375.
4. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 2002; 22: 920-930.
5. Nagy V, Bozdagi O, Matynia A, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 2006; 26: 1923-1934.
6. Wright JW, Harding JW. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast 2009; 2009: 579382.
7. Dziembowska M, Milek J, Janusz A, et al. Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci 2012; 32: 14538-1447.
8. Wiera G, Wojtowicz T, Lebida K, et al. Long term potentiation affects intracellular metalloproteinases activity in the mossy fiber-CA3 pathway. Mol Cell Neurosci 2012; 50: 147-159.
9. Kovalska M, Kovalska L, Mikuskova K, Adamkov M, Tatarkova Z, Lehotsky J. P-ERK involvement in the neuroprotection exerted by ischemic preconditioning in rat hippocampus subjected to four vessel occlusion. J Physiol Pharmacol 2014; 65: 767-776.
10. Wiera G, Wozniak G, Bajor M, Kaczmarek L, Mozrzymas JW. Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity. Hippocampus 2013; 23: 529-543.
11. Kaliszewska A, Bijata M, Kaczmarek L, Kossut M. Experience-dependent plasticity of the barrel cortex in mice observed with 2-DG brain mapping and c-Fos: effects of MMP-9 KO. Cereb Cortex 2012; 22: 2160-2170.
12. Mizoguchi H, Yamada K, Nabeshima T. Matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer's disease, and epilepsy. Biochem Res Int 2011; 2011: 681385.
13. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46: 94-102.
14. Szepesi Z, Bijata M, Ruszczycki B, Kaczmarek L, Wlodarczyk J. Matrix metalloproteinases regulate the formation of dendritic spine head protrusions during chemically induced long-term potentiation. PLoS One 2013; 8: e63314.
15. Bozdagi O, Nagy V, Kwei KT, Huntley GW. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol 2007; 98: 334-444.
16. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci USA 2008; 105: 19520-19525.
17. Michaluk P, Wawrzyniak M, Alot P, et al. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 2011; 124: 3369-3380.
18. Wilczynski GM, Konopacki FA, Wilczek E, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008;180: 1021-1035.
19. Wojtowicz T, Mozrzymas JW. Late phase of long-term potentiation in the mossy fiber-CA3 hippocampal pathway is critically dependent on metalloproteinases activity. Hippocampus 2010; 20: 917-921.
20. Wojtowicz T, Mozrzymas JW. Matrix metalloprotease activity shapes the magnitude of EPSPs and spike plasticity within the hippocampal CA3 network. Hippocampus 2014; 24: 135-153.
21. Kusek M, Tokarski K, Hess G. Repeated restraint stress enhances glutamatergic transmission in the paraventricular nucleus of the rat hypothalamus. J Physiol Pharmacol 2013; 64: 565-570.
22. Graves AR, Moore SJ, Bloss EB, Mensh BD, Kath WL, Spruston N. Hippocampal pyramidal neurons comprise two distinct cell types that are countermodulated by metabotropic receptors. Neuron 2012; 76: 776-789.
23. Dziembowska M, Pretto DI, Janusz A, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013; 161A: 1897-1903.
24. Gkogkas CG, Khoutorsky A, Cao R, et al. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep 2014; 9: 1742-1755.
25. Janusz A, Milek J, Perycz M, et al. The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci 2013; 33: 18234-18241.
26. Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci 2014; 34: 9867-9879.
27. Makino H, Malinow R. AMPA receptor incorporation into synapses during LTP: the role of lateral movement and exocytosis. Neuron 2009; 64: 381-390.
28. Yokoi N, Fukata M, Fukata Y. Synaptic plasticity regulated by protein-protein interactions and posttranslational modifications. Int Rev Cell Mol Biol 2012; 297: 1-43.
29. Opazo P, Sainlos M, Choquet D. Regulation of AMPA receptor surface diffusion by PSD-95 slots. Curr Opin Neurobiol 2012; 22: 453-460.
30. Cathala L, Holderith NB, Nusser Z, DiGregorio DA, Cull- Candy SG. Changes in synaptic structure underlie the developmental speeding of AMPA receptor-mediated EPSCs. Nat Neurosci 2005; 8: 1310-1318.
31. Conant K, Wang Y, Szklarczyk A, Dudak A, Mattson MP, Lim ST. Matrix metalloproteinase-dependent shedding of intercellular adhesion molecule-5 occurs with long-term potentiation. Neuroscience 2010; 166: 508-521.
32. Peixoto RT, Kunz PA, Kwon H, et al. Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuron 2012; 76: 396-409.
33. Gorkiewicz T, Szczuraszek K, Wyrembek P, Michaluk P, Kaczmarek L, Mozrzymas JW. Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons. Hippocampus 2010; 20: 1105-1108.
34. Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 2009; 29: 6007-6012.
35. Lonskaya I, Partridge J, Lalchandani RR, et al. Soluble ICAM-5, a product of activity dependent proteolysis, increases mEPSC frequency and dendritic expression of GluA1. PLoS One 2013; 8: e69136.
36. Fragkouli A, Papatheodoropoulos C, Georgopoulos S, et al. Enhanced neuronal plasticity and elevated endogenous sAPPalpha levels in mice over-expressing MMP9. J Neurochem 2012; 121: 239-251.
37. Fisher KE, Fei Q, Laird ER, et al. Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. Biochemistry 2002; 41: 8289-8297.